Bioinformatics Analyses Identify Shared Differentially Expressed Genes in Non-Tuberculosis and Tuberculosis Pulmonary Diseases ()
1. Introduction
Pulmonary infections caused by nontuberculous mycobacteria (NTM) and Mycobacterium tuberculosis (TB) represent a growing global health challenge, with overlapping clinical presentations but divergent therapeutic requirements [1]. While TB remains a leading infectious killer worldwide (10.6 million cases, 1.3 million deaths in 2022), NTM infections are increasingly recognized as emerging threats, with annual incidence rising by 8.2% among immunocompromised populations and chronic lung disease patients [2]. Despite shared anatomical tropism, these pathogens elicit distinct immune responses: TB drives robust Th1 polarization via IL-12/IFN-γ signaling, whereas NTM evades clearance through TLR2-dependent immunosuppressive cytokine production (e.g., IL-10) [3].
Current diagnostic paradigms relying on microbiological identification face critical limitations, with 34% of NTM cases misclassified as TB during initial assessment in multicenter cohorts [4]. This diagnostic ambiguity reflects incomplete understanding of their molecular signatures. While transcriptomic studies have characterized individual diseases—NTM blood signatures revealing IFNG suppression [5] and TB studies identifying NOD2 downregulation [6]—systematic comparisons of their host response landscapes remain absent. A 2023 review highlights this gap, noting that “no study has yet resolved shared molecular pathways with opposing regulatory trends across mycobacterial infections” [7].
Recent advances in bioinformatics now enable integrative analysis of public transcriptomic datasets to decode disease-specific adaptations. For instance, the RECON method developed for cross-cohort infectious disease analysis [8] has revealed conserved immune modules in viral infections. Leveraging such approaches, we hypothesized that comparative analysis of NTM and TB blood transcriptomes would reveal:
1) Conserved immune pathways underlying mycobacterial persistence
2) Bidirectional regulation of metabolic genes driving disease-specific outcomes
3) Novel neutrophil-mediated mechanisms contributing to immunopathology
4) Our study addresses three critical gaps:
The molecular basis for NTM’s attenuated inflammation (e.g., TGF-β dominance) versus TB’s NLRP3 inflammasome hyperactivation [9]. The role of understudied innate immune checkpoints (e.g., IRAK3, a negative TLR regulator) in chronic infection persistence [10]. Neutrophil extracellular trap (NET) formation’s dual role in mycobacterial containment versus tissue damage, as shown in recent M. avium and TB models [11].
Current host-directed therapies (HDTs) for mycobacterial infections primarily target TB, focusing on immune potentiators (e.g., IFN-γ) or autophagy inducers. However, HDT development for NTM lags due to limited understanding of shared host pathways. By comparing transcriptional landscapes of NTM and TB, this study identifies conserved immune checkpoints (e.g., IRAK3, CD28) that may enable dual-targeted HDT strategies across mycobacterial diseases.
2. Method
2.1. Data Acquisition and Preprocessing
2.1.1. Data Sources
Dataset Selection Criteria: GSE97298 and GSE83456 were selected based on:
1) Human whole-blood transcriptomes from pulmonary infection patients;
2) Inclusion of both NTM/TB and matched healthy controls;
3) Platform compatibility (Affymetrix/Illumina) for cross-dataset normalization.
NTM Cohort: Gene Expression Omnibus (GEO) dataset GSE97298 (https://www.ncbi.nlm.nih.gov/geo/) [12], containing whole-blood transcriptomes from 32 pulmonary NTM patients and 9 healthy controls.
TB Cohort: GEO dataset GSE83456 [13], including 45 active TB patients and 61 controls.
Ethical Compliance: All data was de-identified and publicly available under GEO’s data usage agreements.
2.1.2. Preprocessing:
1) Raw Data Processing:
Affymetrix CEL files: Normalized using the RMA algorithm in the affy R package (v1.78.0) [14].
Illumina IDAT files: Processed with limma (v3.56.0) using neqc normalization for background correction and quantile normalization [15].
2) Batch Correction: Combat algorithm in sva (v3.48.0) [16] adjusted for batch effects (NTM: GPL11532 vs. TB: GPL10558).
2.2. Differential Expression Analysis
2.2.1. DEG Identification:
Conducted separately for NTM and TB cohorts using limma with linear models.
Thresholds: |log2FC| ≥ 1.5, adjusted *p* (FDR) < 0.05 (Benjamini-Hochberg correction).
2.2.2. Gene Annotation
Mapped probes to gene symbols using Bioconductor annotation packages:
hugene11sttranscriptcluster.db (v8.8.0) for NTM
illuminaHumanv4.db (v1.26.0) for TB
2.3. Functional Enrichment Analysis
1) Tools: WebGestalt (2024 release, https://www.webgestalt.org) [17]:
Parameters: Over-Representation Analysis (ORA), FDR < 0.05, minimum 5 genes per category.
Reference set: Human genome (GRCh38, Ensembl v104).
2) Metascape (https://metascape.org) [18]:
Integrated GO, KEGG, and Reactome databases.
Significance threshold: *p* < 1 × 10−3 after Bonferroni correction.
2.4. Protein-Protein Interaction (PPI) Networks
STRING Database (v12.0, https://string-db.org) [19]: Interaction confidence score > 0.7 (high confidence). Excluded disconnected nodes. Cytoscape (v3.9.1) [20]: Network visualization and topological analysis. Hub genes identified using: cytoHubba (v1.6.1) [21] (Maximal Clique Centrality algorithm). MCODE (v2.0.0) [22] (cluster score > 5).
2.5. Statistical Validation
2.5.1. Co-Expression Analysis
Spearman correlation between ELANE and DEFA4 calculated via Hmisc R package (v5.1-0). Significance threshold: *p* < 0.001.
2.5.2. Pathway Inference
KEGG pathway reconstruction (hsa04621: NOD-like receptor signaling) performed using pathview (v1.40.0) [23].
2.6. Software and Reproducibility
R Environment: v4.3.1 with critical packages:ggplot2 (v3.4.2) [24] for visualization. ComplexHeatmap (v2.16.0) [25] for hierarchical clustering.
2.7. Study Flowchart
Figure 1 is the work flow of study.
Figure 1. Workflow of integrated bioinformatics analysis for NTM PD and TB PD characterization.
3. Results
3.1. Distinct Transcriptional Landscapes Characterize NTM and TB Infections
In the NTM cohort (GSE97298), comparative analysis of 32 patients versus 9 controls identified 349 differentially expressed genes (DEGs) under stringent thresholds (|log2FC| ≥1.5, FDR < 0.05), with 53 upregulated and 296 downregulated genes. Notably, interferon-gamma (IFNG), a critical mediator of anti-mycobacterial immunity anti-mycobacterial immunity (Figure 2), showed marked suppression (log2FC = -2.1, *p* = 1.2 × 10−5), while the negative TLR regulator IRAK3 was significantly elevated (log2FC = +0.62, *p* = 0.003).
3.1.1. Differential Gene Expression Profiles
in NTM and TB Infections
(a) (b)
Figure 2. (a) Volcano plots of differentially expressed genes (DEGs) in NTM cohorts; (b) Volcano plots of differentially expressed genes (DEGs) in TB cohorts.
The TB cohort (GSE83456) exhibited more pronounced transcriptional alterations, with 756 DEGs detected between 45 patients and 61 controls. Key findings included downregulation of the pattern recognition receptor NOD2 (log2FC = -1.10, *p* = 4.5 × 10−6) and metalloproteinase MMP9 (log2FC = −0.71, *p* = 0.001), contrasting with upregulation of lymphoid enhancer-binding factor 1 (LEF1, log2FC = +0.79, *p* < 0.001), a transcription factor governing T-cell differentiation. Hierarchical clustering (Figure 3) revealed disease-specific patterns: NTM patients showed prominent upregulation of antimicrobial effectors (CLEC4D, BPI), while TB signatures were dominated by T-cell activation markers (LEF1, CD28).
3.1.2. Heatmap Visualization of Top DEGs
(a)
(b)
Figure 3. (a) Hierarchical clustering of top 50 upregulated and downregulated genes in NTM_PD; (b) Hierarchical clustering of top 50 upregulated and downregulated genes in TB.
3.2. Shared Genetic Architecture with Divergent Regulatory
Dynamics
Venn analysis (Figure 4) identified 48 genes common to both infections, representing 13.8% (48/349) of NTM DEGs and 6.1% (48/784) of TB DEGs. Striking bidirectional regulation patterns emerged upon cross-disease comparison (Table 1 & Table 2):
Figure 4. Intersection analysis identified 48 genes common to both infections.
Table 1. Differential expression analysis of 48 shared genes in NTM (GSE97298).
Gene |
logFC |
AveExpr |
t |
P.Value |
adj.P.Val |
B |
Relative Change |
DMXL2 |
0.612 |
7.337 |
4.750 |
0.000 |
0.002 |
2.655 |
Up |
CREG1 |
0.807 |
7.012 |
4.469 |
0.000 |
0.003 |
1.797 |
Up |
TCN2 |
0.762 |
4.057 |
4.327 |
0.000 |
0.005 |
1.372 |
Up |
KCNJ2 |
0.615 |
6.874 |
4.209 |
0.000 |
0.006 |
1.022 |
Up |
PLSCR1 |
0.690 |
6.335 |
3.407 |
0.001 |
0.028 |
−1.234 |
Up |
SLC26A8 |
0.827 |
4.695 |
3.375 |
0.002 |
0.030 |
−1.317 |
Up |
IRAK3 |
0.620 |
6.739 |
3.315 |
0.002 |
0.033 |
−1.476 |
Up |
SHOC1 |
0.619 |
5.351 |
3.177 |
0.003 |
0.043 |
−1.830 |
Up |
CLEC4D |
0.735 |
5.191 |
2.849 |
0.007 |
0.076 |
−2.640 |
Up |
NOD2 |
0.631 |
5.634 |
2.828 |
0.007 |
0.079 |
−2.690 |
Up |
GPR84 |
0.609 |
3.641 |
2.747 |
0.009 |
0.090 |
−2.878 |
Up |
ELANE |
1.022 |
4.523 |
2.744 |
0.009 |
0.090 |
−2.886 |
Up |
BPI |
1.042 |
5.049 |
2.572 |
0.014 |
0.118 |
−3.275 |
Up |
FOLR3 |
0.789 |
5.970 |
2.468 |
0.017 |
0.136 |
−3.500 |
Up |
ANKRD22 |
0.860 |
3.756 |
2.445 |
0.018 |
0.140 |
−3.549 |
Up |
DEFA3 |
0.642 |
10.427 |
2.343 |
0.024 |
0.162 |
−3.763 |
Up |
CEACAM6 |
0.783 |
3.133 |
2.323 |
0.025 |
0.166 |
−3.804 |
Up |
DEFA4 |
1.212 |
5.709 |
2.133 |
0.038 |
0.214 |
−4.180 |
Up |
FCGR1A |
0.600 |
7.846 |
2.051 |
0.046 |
0.234 |
−4.334 |
Up |
MMP9 |
0.610 |
7.048 |
2.044 |
0.047 |
0.236 |
−4.346 |
Up |
LDHB |
−1.859 |
7.453 |
−8.218 |
0.000 |
0.000 |
13.650 |
Down |
LYRM4 |
−0.684 |
4.245 |
−6.501 |
0.000 |
0.000 |
8.214 |
Down |
NELL2 |
−1.067 |
5.112 |
−5.138 |
0.000 |
0.001 |
3.863 |
Down |
OCIAD2 |
−0.844 |
5.058 |
−5.017 |
0.000 |
0.001 |
3.484 |
Down |
CSTA |
−1.331 |
6.600 |
−4.706 |
0.000 |
0.002 |
2.520 |
Down |
GPR183 |
−0.693 |
6.696 |
−4.624 |
0.000 |
0.002 |
2.269 |
Down |
AQP3 |
−0.671 |
5.845 |
−4.525 |
0.000 |
0.003 |
1.966 |
Down |
HOOK1 |
−0.595 |
2.424 |
−4.383 |
0.000 |
0.004 |
1.539 |
Down |
CD96 |
−0.646 |
7.067 |
−4.229 |
0.000 |
0.006 |
1.082 |
Down |
EPHX2 |
−0.750 |
3.264 |
−4.177 |
0.000 |
0.006 |
0.929 |
Down |
KLRB1 |
−0.943 |
5.319 |
−4.079 |
0.000 |
0.007 |
0.643 |
Down |
EPHA4 |
−0.625 |
4.458 |
−4.068 |
0.000 |
0.008 |
0.611 |
Down |
INPP4B |
−0.635 |
5.923 |
−4.036 |
0.000 |
0.008 |
0.516 |
Down |
CD40LG |
−0.644 |
5.109 |
−3.988 |
0.000 |
0.009 |
0.379 |
Down |
CD28 |
−0.770 |
6.217 |
−3.984 |
0.000 |
0.009 |
0.367 |
Down |
TESPA1 |
−0.683 |
7.100 |
−3.778 |
0.000 |
0.014 |
−0.218 |
Down |
TXK |
−0.591 |
6.454 |
−3.618 |
0.001 |
0.019 |
−0.662 |
Down |
FHIT |
−0.659 |
4.518 |
−3.522 |
0.001 |
0.023 |
−0.924 |
Down |
VSIG1 |
−0.643 |
4.492 |
−3.412 |
0.001 |
0.028 |
−1.220 |
Down |
GAL3ST4 |
−0.636 |
4.245 |
−3.366 |
0.002 |
0.030 |
−1.342 |
Down |
ZNF439 |
−0.680 |
3.410 |
−3.319 |
0.002 |
0.032 |
−1.464 |
Down |
SH2D1B |
−0.729 |
4.744 |
−3.175 |
0.003 |
0.043 |
−1.837 |
Down |
LEF1 |
−0.673 |
7.615 |
−3.135 |
0.003 |
0.047 |
−1.939 |
Down |
FCMR |
−0.607 |
8.021 |
−3.131 |
0.003 |
0.047 |
−1.948 |
Down |
LRRN3 |
−0.790 |
3.272 |
−3.085 |
0.003 |
0.051 |
−2.063 |
Down |
GZMK |
−0.862 |
6.327 |
−3.007 |
0.004 |
0.058 |
−2.256 |
Down |
STRBP |
−0.697 |
4.375 |
−2.890 |
0.006 |
0.071 |
−2.542 |
Down |
BANK1 |
−0.729 |
4.934 |
−2.639 |
0.011 |
0.106 |
−3.124 |
Down |
adj.P.Val thresholds: NTM (FDR < 0.05), TB (FDR < 0.001). Full gene lists are provided in Supplementary Tables.
Table 2. Differential expression analysis of 48 shared genes in TB (GSE83456).
Gene |
logFC |
AveExpr |
t |
P.Value |
adj.P.Val |
B |
Relative Change |
DMXL2 |
−0.830 |
−0.152 |
−7.225 |
0.000 |
0.000 |
14.122 |
Down |
CREG1 |
−0.655 |
−0.145 |
−6.642 |
0.000 |
0.000 |
11.335 |
Down |
TCN2 |
−1.452 |
−0.099 |
−9.845 |
0.000 |
0.000 |
27.327 |
Down |
KCNJ2 |
−0.967 |
−0.223 |
−9.910 |
0.000 |
0.000 |
27.661 |
Down |
PLSCR1 |
−1.726 |
−0.356 |
−10.333 |
0.000 |
0.000 |
29.835 |
Down |
SLC26A8 |
−1.417 |
−0.053 |
−10.403 |
0.000 |
0.000 |
30.196 |
Down |
IRAK3 |
−0.795 |
−0.050 |
−7.872 |
0.000 |
0.000 |
17.300 |
Down |
SHOC1 |
−0.594 |
−0.160 |
−4.088 |
0.000 |
0.000 |
0.624 |
Down |
CLEC4D |
−1.329 |
−0.226 |
−9.468 |
0.000 |
0.000 |
25.390 |
Down |
NOD2 |
−1.098 |
−0.043 |
−9.038 |
0.000 |
0.000 |
23.190 |
Down |
GPR84 |
−1.175 |
−0.140 |
−7.772 |
0.000 |
0.000 |
16.802 |
Down |
ELANE |
−0.818 |
−0.538 |
−3.536 |
0.001 |
0.001 |
−1.229 |
Down |
BPI |
−0.641 |
−0.233 |
−3.101 |
0.002 |
0.005 |
−2.541 |
Down |
FOLR3 |
−0.978 |
−0.013 |
−5.158 |
0.000 |
0.000 |
4.745 |
Down |
ANKRD22 |
−3.849 |
−1.016 |
−20.352 |
0.000 |
0.000 |
76.875 |
Down |
DEFA3 |
−0.820 |
−0.536 |
−2.939 |
0.004 |
0.008 |
−2.992 |
Down |
CEACAM6 |
−0.934 |
−0.373 |
−3.687 |
0.000 |
0.001 |
−0.745 |
Down |
DEFA4 |
−0.703 |
−0.556 |
−2.377 |
0.019 |
0.033 |
−4.398 |
Down |
FCGR1A |
−3.345 |
−1.028 |
−15.376 |
0.000 |
0.000 |
54.967 |
Down |
MMP9 |
−0.705 |
−0.128 |
−3.774 |
0.000 |
0.001 |
−0.454 |
Down |
LDHB |
0.609 |
0.146 |
7.764 |
0.000 |
0.000 |
16.765 |
Up |
LYRM4 |
0.630 |
0.033 |
5.599 |
0.000 |
0.000 |
6.613 |
Up |
NELL2 |
1.226 |
0.111 |
9.642 |
0.000 |
0.000 |
26.282 |
Up |
OCIAD2 |
0.645 |
0.023 |
7.373 |
0.000 |
0.000 |
14.843 |
Up |
CSTA |
−0.895 |
−0.200 |
−8.354 |
0.000 |
0.000 |
19.716 |
Up |
GPR183 |
0.864 |
−0.037 |
8.546 |
0.000 |
0.000 |
20.686 |
Up |
AQP3 |
0.639 |
0.025 |
5.547 |
0.000 |
0.000 |
6.388 |
Up |
HOOK1 |
1.072 |
0.312 |
9.195 |
0.000 |
0.000 |
23.989 |
Up |
CD96 |
0.635 |
−0.094 |
7.480 |
0.000 |
0.000 |
15.363 |
Up |
EPHX2 |
0.819 |
0.286 |
7.269 |
0.000 |
0.000 |
14.333 |
Up |
KLRB1 |
0.821 |
−0.007 |
7.502 |
0.000 |
0.000 |
15.475 |
Up |
EPHA4 |
0.842 |
0.108 |
6.267 |
0.000 |
0.000 |
9.592 |
Up |
INPP4B |
0.721 |
0.075 |
6.507 |
0.000 |
0.000 |
10.703 |
Up |
CD40LG |
0.908 |
0.021 |
6.993 |
0.000 |
0.000 |
13.000 |
Up |
CD28 |
0.868 |
−0.036 |
7.723 |
0.000 |
0.000 |
16.562 |
Up |
TESPA1 |
0.876 |
0.128 |
8.395 |
0.000 |
0.000 |
19.924 |
Up |
TXK |
0.818 |
0.103 |
6.911 |
0.000 |
0.000 |
12.609 |
Up |
FHIT |
0.804 |
0.297 |
6.511 |
0.000 |
0.000 |
10.724 |
Up |
VSIG1 |
0.655 |
0.176 |
6.238 |
0.000 |
0.000 |
9.462 |
Up |
GAL3ST4 |
0.600 |
0.154 |
5.534 |
0.000 |
0.000 |
6.335 |
Up |
ZNF439 |
0.606 |
0.117 |
6.858 |
0.000 |
0.000 |
12.356 |
Up |
SH2D1B |
0.668 |
−0.178 |
4.116 |
0.000 |
0.000 |
0.725 |
Up |
LEF1 |
0.792 |
0.192 |
8.270 |
0.000 |
0.000 |
19.291 |
Up |
FCMR |
0.894 |
−0.027 |
9.785 |
0.000 |
0.000 |
27.020 |
Up |
LRRN3 |
1.775 |
0.565 |
8.139 |
0.000 |
0.000 |
18.637 |
Up |
GZMK |
1.083 |
−0.179 |
6.533 |
0.000 |
0.000 |
10.826 |
Up |
STRBP |
0.741 |
−0.066 |
6.485 |
0.000 |
0.000 |
10.603 |
Up |
BANK1 |
0.794 |
−0.038 |
7.089 |
0.000 |
0.000 |
13.464 |
Up |
adj.P.Val thresholds: NTM (FDR < 0.05), TB (FDR < 0.001). Full gene lists are provided in Supplementary Tables.
3.3. Convergent Pathways across Mycobacterial Diseases
Functional enrichment analysis through WebGestalt (2024 release,
https://www.webgestalt.org/)revealed significant over-representation of immune-related processes (FDR < 0.01):
Biological processes:
Regulation of immune system process (GO:0002682, 19 genes); Response to bacterium (GO:0009617, 12 genes) (Table 3).
Molecular functions:
Signaling receptor activity (27.1% of genes); Cytokine binding capacity (14.6%).
Table 3. Top 10 enriched pathways and processes.
Term ID |
Description |
FDR |
Key Genes |
GO:0002682 |
Regulation of immune system process |
2.37 × 10−6 |
CD28, IRAK3, NOD2 |
GO:0006955 |
Immune response |
2.37 × 10−6 |
BPI, CLEC4D, FCGR1A |
GO:0002684 |
Positive regulation of immune system process |
4.65 × 10−6 |
LEF1, CD40LG |
GO:0002252 |
Immune effector process |
4.82 × 10−6 |
ELANE, GPR183 |
GO:0050776 |
Regulation of immune response |
2.31 × 10−5 |
TXK, TESPA1 |
GO:0009617 |
Response to bacterium |
7.39 × 10−5 |
NOD2, BPI |
GO:0002768 |
Immune response-regulating cell surface signaling |
1.24 × 10−4 |
CD96, KLRB1 |
R-HSA-168249 |
Innate Immune System (Reactome) |
1.44 × 10−4 |
IRAK3, CLEC4D |
GO:0002250 |
Adaptive immune response |
1.44 × 10−4 |
CD28, LEF1 |
Metascape analysis further identified neutrophil degranulation (Reactome R-HSA-6798695, *p* = 2.45 × 10−8) and Fc receptor signaling (GO:0038093, *p* = 1.15 × 10−4) as core pathways. Disease association mapping demonstrated strong links to pulmonary tuberculosis (DisGeNET C0041327, *p* = 1.58 × 10−6) and bacterial infections (C0004623, *p* = 3.98 × 10−8) (Table 4).
Table 4. Top enriched pathways.
GO |
Category |
Description |
Count |
% |
Log10(P) |
Log10(q) |
GO:0009617 |
GO Biological Processes |
response to bacterium |
12 |
25.00 |
−8.98 |
−4.64 |
R-HSA-6798695 |
Reactome Gene Sets |
Neutrophil degranulation |
9 |
18.75 |
−7.61 |
−3.85 |
GO:0002694 |
GO Biological Processes |
regulation of leukocyte activation |
10 |
20.83 |
−7.59 |
−3.85 |
GO:0050778 |
GO Biological Processes |
positive regulation of immune response |
10 |
20.83 |
−7.01 |
−3.57 |
GO:0001818 |
GO Biological Processes |
negative regulation of cytokine production |
7 |
14.58 |
−5.59 |
−2.65 |
GO:0050864 |
GO Biological Processes |
regulation of B cell activation |
4 |
8.33 |
−4.21 |
−1.68 |
GO:0098657 |
GO Biological Processes |
import into cell |
7 |
14.58 |
−3.97 |
−1.49 |
GO:0038093 |
GO Biological Processes |
Fc receptor signaling pathway |
3 |
6.25 |
−3.94 |
−1.48 |
GO:0045861 |
GO Biological Processes |
negative regulation of proteolysis |
4 |
8.33 |
−3.50 |
−1.15 |
GO:0008037 |
GO Biological Processes |
cell recognition |
3 |
6.25 |
−2.86 |
−0.66 |
GO:0002573 |
GO Biological Processes |
myeloid leukocyte differentiation |
3 |
6.25 |
−2.67 |
−0.50 |
GO:0060326 |
GO Biological Processes |
cell chemotaxis |
3 |
6.25 |
−2.33 |
−0.20 |
3.4. Core Regulatory Networks Underlying Host-Pathogen
Interactions
Protein–protein interaction (PPI) network analysis, performed using the STRING database, elucidated key immune pathways significantly enriched among the host response genes. The top enriched immune pathways are summarized in (Table 5). Notably, “Regulation of immune system process” (GO:0002682) exhibited the most significant enrichment (FDR = 1.72 × 10−5), involving 18 genes, with IRAK3, NOD2, and CD28 identified as pivotal regulatory nodes. Similarly, “Positive regulation of immune system process” (GO:0002684) was highly represented (FDR = 1.72 × 10−5), comprising 15 genes, with key contributions from LEF1 and CD40LG. The “Response to bacterium” pathway (GO:0009617) was also significantly enriched (FDR = 0.001), highlighting the involvement of BPI, CLEC4D, and DEFA4. In addition, the “Regulation of innate immune response” pathway (GO:0045088) (FDR = 0.002) and the “Antimicrobial humoral response” pathway (GO:0061844) (FDR = 0.007) were enriched, with IRAK3, FCGR1A, DEFA4, and ELANE serving as central components. Collectively, these results underscore the pivotal role of immune regulatory networks in mediating the host response to pathogen challenge, with several key genes occupying central positions within these pathways.
Table 5. Top enriched immune pathways.
Term ID |
Description |
Genes |
FDR |
Key Genes |
GO:0002682 |
Regulation of immune system process |
18 |
1.72 × 10−5 |
IRAK3, NOD2, CD28 |
GO:0002684 |
Positive regulation of immune system process |
15 |
1.72 × 10−5 |
LEF1, CD40LG |
GO:0009617 |
Response to bacterium |
11 |
0.001 |
BPI, CLEC4D, DEFA4 |
GO:0045088 |
Regulation of innate immune response |
7 |
0.002 |
IRAK3, FCGR1A |
GO:0061844 |
Antimicrobial humoral response |
5 |
0.007 |
DEFA4, ELANE |
3.5. Identification of Core Hub Genes by Integrative Network
Analysis and Internal Validation
Consensus analysis integrating cytoHubba (topological analysis), cytoNCA (node centrality assessment), and MCODE (molecular complex detection) robustly identified neutrophil elastase (ELANE) and defensin alpha 4 (DEFA4) as central hub genes within the protein–protein interaction network (Figure 5). Both ELANE and DEFA4 were consistently recognized as core regulators by all three computational approaches, as demonstrated by their intersection in the Venn diagram.
To further substantiate these findings, internal validation was performed using the original dataset. The expression levels of ELANE and DEFA4 were found to be significantly different (P < 0.05), confirming their pivotal roles with robust statistical significance (Figure 6(a), Figure 6(b)). This internal validation provides additional confidence in the reliability of the computational predictions and underscores the central regulatory functions of ELANE and DEFA4 within the immune response network.
3.6. Functional Synergy Between ELANE and DEFA4
A robust and consistent positive correlation was observed between ELANE and
Figure 5. Venn diagram of hub genes.
Note: cytoHubba (topological analysis), cytoNCA (node centrality), MCODE (molecular complex detection). Intersection (3 methods): ELANE, DEFA4.
(a)
Note:ELANE is significantly upregulated in NTM patients (n = 32) compared to healthy controls (n = 9) (Wilcoxon test, P = 0.003). Red (G1: NTM), blue (G2: Healthy); asterisks denote significance (**P < 0.01, P < 0.01).
(b)
Figure 6. (a) ELANE Expression in NTM vs. Healthy Controls; (b) ELANE Expression in TB vs. Healthy Controls.
Note: Spearman correlation analysis reveals a strong positive relationship between ELANE and DEFA4 in NTM (r = 0.86, P < 0.001).
(a)
Note: ELANE and DEFA4 exhibit strong positive correlation in TB (r = 0.86, r = 0.94, P < 0.001).
(b)
Figure 7. (a) ELANE-DEFA4 Correlation in NTM; (b) ELANE-DEFA4 Correlation in TB.
DEFA4 expression across both cohorts, as demonstrated by Spearman correlation coefficients of r = 0.86 and r = 0.94, respectively (P < 0.001 for both comparisons). Notably, this strong co-expression was evident even though DEFA4 did not independently exhibit significant differential expressions. These findings indicate a potential co-regulatory mechanism underlying their involvement in antimicrobial responses. Biologically, both ELANE and DEFA4 are intimately associated with neutrophil-mediated host defense, with ELANE participating in neutrophil degranulation and DEFA4 functioning as a key antimicrobial peptide. This functional synergy suggests that, while DEFA4 alone may not be differentially expressed, its expression is tightly coordinated with ELANE and may contribute cooperatively to pathogen clearance. The scatter plots in Figure 7(a), Figure 7(b) further illustrate the strong positive relationship between ELANE and DEFA4 in both NTM and TB cohorts, underscoring their collective role in the immune response to mycobacterial infection.
4. Discussion
The comparative transcriptomic landscape of nontuberculous mycobacterial (NTM) and tuberculous (TB) pulmonary infections reveals conserved yet divergent host responses, offering novel insights into their distinct clinical trajectories. Our identification of 48 shared DEGs with bidirectional regulation—particularly metabolic and immune regulators—suggests a dynamic interplay between pathogen persistence strategies and host adaptation. Below, we contextualize these findings within existing knowledge and propose testable mechanistic hypotheses.
4.1. Metabolic Reprogramming as a Disease-Specific Adaptive Strategy
The bidirectional regulation of LDHB (NTM: log2FC = −1.86 vs. TB: +0.61) highlights divergent host metabolic adaptations. In TB, LDHB upregulation may fuel glycolytic reprogramming to support pro-inflammatory macrophage responses, consistent with prior reports linking enhanced glycolysis to M. tuberculosis control [26]. Conversely, LDHB suppression in NTM could promote a metabolically quiescent state conducive to chronic infection, akin to metabolic adaptations observed in latent viral infections [27]. This dichotomy aligns with clinical observations of TB’s acute inflammation versus NTM’s indolent course, suggesting that targeting metabolic checkpoints (e.g., lactate transporters) might recalibrate host responses.
4.2. Context-Dependent Roles of Pattern Recognition Receptors
The paradoxical upregulation of NOD2 in NTM (log2FC = +0.63, FDR = 0.007) contrasts sharply with its suppression in TB (log2FC = −1.10, FDR < 0.001). While NOD2 typically activates NF-κB via RIPK2 in TB [28], its role in NTM may involve non-canonical pathways such as autophagy induction or mitochondrial antiviral signaling (MAVS) crosstalk [29]. This hypothesis is supported by NOD2’s known capacity to trigger LC3-associated phagocytosis, a mechanism exploited by intracellular pathogens to evade lysosomal degradation [30].
4.3. IRAK3 and CD28: Gatekeepers of Immune Homeostasis
The inverse regulation of IRAK3 (NTM: +0.62 vs. TB: −0.80) underscores its role as a TLR signaling rheostat. In NTM, elevated IRAK3 likely dampens TLR-driven inflammation through SOCS1-mediated ubiquitination [31], fostering immune tolerance. In TB, IRAK3 downregulation may permit hyperactive TLR responses that, while enhancing bacterial clearance, risk collateral tissue damage—a phenomenon observed in murine TB models with IRAK3 deficiency [32]. Similarly, CD28 upregulation in TB (log2FC = +0.87) correlates with enhanced T-cell co-stimulation and IFN-γ production [33], whereas its suppression in NTM may reflect T-cell exhaustion, as seen in chronic viral infections [34].
4.4. Neutrophil Activation: A Double-Edged Sword
The strong *ELANE-DEFA4* correlation (r = 0.86, *p* < 0.001) in NTM suggests coordinated neutrophil degranulation, potentially limiting bacterial dissemination via NETosis [35]. However, ELANE’s downregulation in TB (log2FC = −0.82) may reflect M. tuberculosis evasion strategies, such as secretion of nuclease EsxA to degrade NETs [36]. These findings echo recent work showing that excessive NETosis exacerbates lung pathology in murine TB [37], highlighting the need for therapeutic strategies that balance antimicrobial efficacy and immunopathology.
4.5. Limitations and Future Directions
Our study has limitations. First, the use of whole-blood transcriptomes may obscure tissue-specific responses, as pulmonary immune activity often diverges from peripheral signatures [38]. Second, sample size disparities (NTM: *n* = 32 vs. TB: *n* = 45) could affect statistical power, though our FDR-controlled analysis mitigates this risk [39]. Third, Potential confounders including age, sex, comorbidities (e.g., COPD), and prior treatments were not analyzed due to limited metadata in public datasets. Future studies should incorporate covariate-adjusted models to validate target robustness. Also, future work should validate mechanistic links:
1) In vitro NETosis assays measuring ELANE/DEFA4 release in NTM/TB-infected neutrophils;
2) Murine models evaluating NET inhibition (e.g., DNase I) on lung pathology;
3) Spatial transcriptomics to localize ELANE+ neutrophils in patient lung tissues.
4.6. Translational Implications
The bidirectional regulators identified here—particularly IRAK3 and CD28—represent promising targets for host-directed therapies. IRAK3 inhibitors (e.g., ND-2158) have shown efficacy in dampening pathological inflammation in sepsis models [40], while CD28 agonists are being explored to reverse T-cell exhaustion in chronic infections [41]. Validating these interventions in mycobacterial models could pave the way for precision immunotherapies tailored to infection context.
5 Conclusion
Our integrative analysis of nontuberculous mycobacterial (NTM) and tuberculous (TB) pulmonary infections uncovers a conserved yet divergent transcriptional architecture that underpins their distinct clinical phenotypes. The identification of 48 bidirectionally regulated genes—spanning metabolic, innate, and adaptive immune pathways—reveals how shared molecular frameworks are dynamically repurposed across infections. Key findings include:
1) Metabolic Polarization: LDHB suppression in NTM versus its induction in TB highlights context-dependent reprogramming of glycolysis, suggesting metabolic modulation as a strategy to recalibrate inflammation.
2) Dual-Faced Immune Checkpoints: The inverse regulation of IRAK3 (NTM: ↑ vs. TB: ↓) and CD28 (TB: ↑ vs. NTM: ↓) positions these nodes as gatekeepers balancing pathogen clearance and immunopathology.
3) Neutrophil Dichotomy: The *ELANE-DEFA4* co-regulation network in NTM points to neutrophil degranulation as a double-edged sword—protective in containment but potentially deleterious in TB through NETosis-mediated tissue injury.
4) These findings establish IRAK3 and CD28 as priority candidates for diagnostic biomarker panels and host-directed therapies. While our computational framework provides actionable hypotheses, functional validation in preclinical models is essential to confirm causality. Ultimately, decoding the bidirectional plasticity of host responses advances precision medicine strategies for mycobacterial diseases, where tailored immunomodulation may optimize outcomes across the infection spectrum.
Acknowledgements
The authors acknowledge the following contributions to this work:
Data Resources: We thank the National Center for Biotechnology Information (NCBI) for maintaining the Gene Expression Omnibus (GEO) database, which provided foundational datasets for this study (GSE97298 and GSE83456).
Open-Source Tools: This study utilized critical bioinformatics tools, including the R/Bioconductor framework, STRING database, and Cytoscape platform. We express gratitude to their developer communities for advancing open science.
Ethics Approval and Consent to Participate
Ethical approval was not required for this study as it utilized publicly available, de-identified transcriptomic datasets from the Gene Expression Omnibus (GEO) repository (accession numbers GSE97298 and GSE83456). No human or animal experiments were conducted.
Consent for Publication
Not applicable. This study did not involve individual participants, personal data, or identifiable human materials.
Data Availability
The datasets analyzed in this study are publicly accessible through the NCBI Gene Expression Omnibus (GEO) under the following accession numbers:
NTM cohort: GSE97298
TB cohort: GSE83456
Author Contributions
Liang Chaoyue (L. C. Y.) and Luo Hongyun (L. H. Y.) contributed equally to this work.
Liang Chaoyue (L. C. Y.): Conceptualization, Methodology, Software, Formal Analysis, Data Curation, Visualization, Writing-Original Draft, Writing—Review & Editing.
Luo Hongyun (L. H. Y.): Investigation, Data Curation, Validation, Writing—Original Draft, Literature Retrieval.
Zhou Ni (Z. N.): Data Collection, Formal Analysis.
Mu Wenmei: Data Collection, Formal Analysis.
Yang Zhicheng (Y. Z. C.): Data Science, Resources, Validation.
All authors critically reviewed and approved the final manuscript.
NOTES
*These authors contributed equally to this work.
#Corresponding author.